Sheaff Brock Investment Advisors’s Aratana Therapeutics, Inc. PETX Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10,000	Closed	-$58K	–	553
2018 Q3	$58K	Sell	10,000 -20,000	-67%	-$99.9K	0.01%	509
2018 Q2	$128K	Sell	30,000 -61,000	-67%	-$308K	0.01%	502
2018 Q1	$401K	Sell	91,000 -10,000	-10%	-$44.6K	0.04%	299
2017 Q4	$531K	Buy	101,000 +30,000	+42%	+$184K	0.07%	246
2017 Q3	$435K	Sell	71,000 -10,000	-12%	-$63.3K	0.06%	280
2017 Q2	$586K	Buy	+81,000	New	+$498K	0.08%	246

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GPGA

Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sheaff Brock Investment Advisors's PETX Position: Q4 2018 in Review

Sheaff Brock Investment Advisors sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2018, closing a stake of 10,000 shares — an estimated $58K sold.

Sheaff Brock Investment Advisors first reported a position in PETX in Q2 2017 and held it in 6 quarters. The position peaked at $586K in Q2 2017. 115 funds tracked by Wall St. Rank hold PETX as of Q4 2018.

Sheaff Brock Investment Advisors reported no remaining Aratana Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
Sheaff Brock Investment Advisors sold 10,000 Aratana Therapeutics, Inc. shares in Q4 2018, an estimated $58K.
Sheaff Brock Investment Advisors first reported a position in Aratana Therapeutics, Inc. in Q2 2017 and held it in 6 quarters.
Sheaff Brock Investment Advisors's Aratana Therapeutics, Inc. position peaked at $586K in Q2 2017.
115 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2018.

Based on Sheaff Brock Investment Advisors's 13F filing for Q4 2018, filed 28 Jan 2019.